IRDiRC-Related Calls

IRDiRC does not provide centralized grants. Its members have a number of funding opportunities available in the field of rare disease research that are in compliance with IRDiRC rules and guidelines. These funding opportunities are listed below.

 

October 2017

Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers – R21 (NIH, USA)

USA
This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

Full details of the call

DEADLINE: October 16, 2017

Preclinical Research in rare diseases: translational steps in large animals (FMR, France)


In the field of rare diseases, understanding the physiopathological mechanisms and moreover the evaluation of innovative therapeutic strategies, rely for a large part on animal models, particularly rodents. Translational research represents a link between exploratory steps of proofs of principle to clinical application in human. In some cases, the use of larger animal models is necessary to confirm the relevance of a concept or to demonstrate the feasibility, the efficiency and the safety of a therapeutic approach in conditions that mimic as closely as possible the human situation. The call for proposals launched by the French Foundation for rare diseases aims to directly support intermediary key steps towards clinical development for patients

Full details of the call

DEADLINE: October 24, 2017 at 5pm (Paris time)

 

Generic call for proposals 2018 (ANR, France)


The ANR is launching its generic call for proposals for the year 2018 (GENERIC CALL FOR PROPOSALS 2018). It is open to all scientific disciplines and all types of research, from the most fundamental projects to applied research conducted as part of a partnership with a company, especially SMEs and very small businesses.

THE GENERIC CALL FOR PROPOSALS 2018 corresponds to the principal “Research and innovation” component of the Work Programme 2018, which has been simplified (link) and is now structured by research theme.

A total of 36 research themes are presented in the framework of the nine societal challenges*.
Three themes fall outside the challenge framework, supporting certain fundamental disciplines.
Eight research themes are cross-disciplinary challenges at the crossroads of several challenges (“Interchallenge” themes).
Every theme corresponds to a scientific evaluation committee (SEC).

For improved disciplinary and cross-disciplinary identification, commensurate with the challenges, the project leader will choose a research theme that corresponds to a scientific evaluation committee (SEC). Various SEC can be relevant to rare diseases research as they are part of the challenge “Life, Health and Well-Being”
Full details of the call (in French)

DEADLINE: 26 October 2017 at 1 pm (Paris time)

 

November 2017

Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01) (NIAMS, USA)

USA
This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical trials for musculoskeletal, rheumatic, or skin diseases or conditions. Research data from observational cohort studies can enhance clinical trial design by providing essential information about disease symptoms, stages and timing of disease progression, comorbid conditions, availability of potential clinical trial participants, and outcomes that are important to patients. CO studies also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in a future trial or trials. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical trial, such as determining the appropriate primary or secondary outcome measures, or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA.

Full details of the call

DEADLINE: November 1, 2017

 

Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers – R01 (NIH, USA)

USA
This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

Research projects submitted to this FOA should focus on palliative and end-of-life care for individuals with advanced, rare diseases and their family caregivers. Studies may consider changing needs that occur across time points and disease progression, as well as ways in which EOLPC and planning can adapt to meet these changing needs. Childhood cancers are not of interest for the purposes of this FOA.

Research projects of interest include, but are not limited to those that:

  • Determine the unique EOLPC needs and preferences (including decision-making) of individuals with advanced, rare diseases and their family caregivers.
  • Contribute seminal data on how needs and preferences of individuals with rare diseases and their family caregivers change across stages of an illness, to provide evidence for future intervention-based studies.
  • Design, test, evaluate, and/or compare EOLPC interventions or models of care to support individuals living with advanced, rare diseases.
  • Design, test, and evaluate, and/or compare EOLPC interventions or models of care to support family caregivers of those living with advanced, rare diseases.
  • To establish key indicators of and appropriate measurements for quality outcomes in individuals with advanced, rare diseases and their family caregivers.
  • Identify transition points at the advanced stages of illness which result in a change in palliative or hospice care needs and develop evidence-based interventions/models of care support during these critical transition points.
  • Foster new research to determine the readiness of individuals with advanced, rare diseases and their families to engage in integrated palliative care.
  • Develop and test innovative technologies for use in palliative and/or hospice care models for individuals with rare diseases.

Full details of the call

DEADLINE: November 5, 2017

nbsp;

Biological response modifier drugs for rare autoimmune diseases (NHS, UK)


The aim of the HTA Programme is to ensure that high quality research information on the effectiveness, costs and broader impact of health technology is produced in the most efficient way for those who use, manage, provide care in or develop policy for the NHS. Topics for research are identified and prioritised to meet the needs of the NHS. Health technology assessment forms a substantial portfolio of work within the National Institute for Health Research and each year about fifty new studies are commissioned to help answer questions of direct importance to the NHS. The studies include both primary research and evidence synthesis.
Research Question:
What is the clinical effectiveness of biological response modifiers (biologics) used for a range of rare autoimmune diseases and are they cost effective?

Full details of the call

DEADLINE: 30 November 2017, 1pm (London time)

 

December 2017

NeuroNEXT Clinical Trials -U01 (NINDS, USA)

USA
This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS’ strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Applicants do not need to be part of the existing NeuroNEXT infrastructure.

Full details of the call

DEADLINES: December 6, 2017

 

February 2018

Project grant: Spring 2018 (CIHR, Canada)


The Project Grant program is designed to capture ideas with the greatest potential to advance health-related fundamental or applied knowledge, health research, health care, health systems, and/or health outcomes. It supports projects with a specific purpose and a defined endpoint. The best ideas may stem from new, incremental, innovative, and/or high-risk lines of inquiry or knowledge translation approaches.

The Project Grant program will:
– support a diverse portfolio of health-related research and knowledge translation projects at any stage, from discovery to application, including commercialization;
– promote relevant collaborations across disciplines, professions, and sectors; and,
– contribute to the creation and use of health-related knowledge.

Full details of the call

DEADLINES: February 6, 2018 for the letter of intent and March 6, 2018 for the application

 

Clinical studies of safety and effectiveness of orphan products research project grant (FDA, USA)

USA
The goal of FDA’s OOPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product being developed will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. Applicants must include in the application’s Background and Significance section documentation to support the assertion that the orphan disease or condition to be studied is a “rare disease or condition” and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.

The grants are available to any foreign or domestic, public or private, for-profit or nonprofit entity (including State and local units of government). Federal agencies that are not part of the Department of Health and Human Services (HHS) may apply. Agencies that are part of HHS may not apply.  For-profit entities must commit to excluding fees or profit in their request for support to receive grant awards. Organizations that engage in lobbying activities are not eligible to receive grant awards.

Full details of the call

DEADLINE: February 7, 2018 

 

August 2018

Natural History Studies for Rare Disease Product Development: Orphan Products Research Project Grant (R01) (FDA, USA)

USA
The objective of FDA’s Orphan Products Natural History Grants Program is to support studies that advance rare disease medical product development through characterization of the natural history of rare diseases/conditions, identification of genotypic and phenotypic subpopulations, and development and/or validation of clinical outcome measures, biomarkers and/or companion diagnostics. The ultimate goal of these natural history studies is to support clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA provides grants for natural history studies that will either assist or substantially contribute to market approval of these products. Applicants must include in the application’s Background and Significance section documentation to support that the estimated prevalence of the orphan disease or condition in the United States (US) is less than 200,000 (or in the case of a vaccine or diagnostic, information to support that the product will be administered to fewer than 200,000 people in the US per year), and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development. Additional information may be required upon request, for example, regarding population estimate and rationale.

Full details of the call

DEADLINES: August 31, 2018 for the letter of intent and October 15, 2018 for the application 

 

Rolling deadline – applications on an ongoing basis

Canadian “Rare Diseases: Models & Mechanisms” Network (RDMM, Canada)

Canada
On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system.

Three categories of Connection applications will be considered:

  1. Novel gene supported by genetic evidence (mutations in the same gene in unrelated patients with a similar phenotype) and functional data is being rapidly sought prior to publication.
  2. Candidate gene for a rare disease in a single patient/family/isolated population such that additional functional data is necessary to support disease-causation.
  3. Known disease gene that is of therapeutic or biological interest to a unique Canadian population or community (e.g. Hutterite, First Nation, French Canadian, patient advocacy group etc.).

Funds Available:
A maximum of $25,000 will be awarded for each catalyst grant.

Eligibility:
Applications may be submitted by any investigator associated with a Canadian Institution.

Full details of the call

 

Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01) (NHGRI, USA)

USA
The Center for Inherited Disease Research (CIDR) high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes or genetic modifications that contribute to human health and disease or to enhance existing collections of well-phenotyped specimens by the addition of genotype or next-generation sequence data. The laboratory specializes in genomic services that cannot be efficiently carried out in individual investigator laboratories. CIDR provides the most up-to-date platforms, services and statistical genetic support. This is an NIH-wide initiative that is managed by NHGRI. Information about the current services offered can be accessed via: http://www.cidr.jhmi.edu.

Applications will be reviewed no later than 120 days after receipt of application with one meeting in each of the following windows: September 2017; November 2017; January 2018; March 2018, April-May 2018; July 2018; September 2018; November 2018; January 2019; March 2019; April-May 2019; July 2019; September 2019; November 2019; January 2020;  March 2020; April-May 2020; July 2020.

Full details of the call